Inoxgen

Nitric oxide, the active ingredient in Inoxgen, is a vasodilator presented as a medical gas for inhalation use. It is employed to manage elevated pulmonary arterial pressure in neonates with pulmonary hypertension, adults with pulmonary hypertension, and patients experiencing acute respiratory distress syndrome.

GNH USA supplies Inoxgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide. The company ensures quality compliance with EU regulations and provides reliable global distribution.

Inoxgen is a pulmonary vasodilator that targets elevated pulmonary arterial pressure in various respiratory conditions.

- Neonatal pulmonary hypertension: reduces pulmonary vascular resistance and improves oxygenation in newborns. - Acute respiratory distress syndrome: lowers pulmonary artery pressure and supports gas exchange in critically ill patients. - Pulmonary hypertension: provides selective pulmonary vasodilation to improve hemodynamics and exercise capacity.

Inhaled nitric oxide may be associated with several adverse reactions, ranging from frequent to rare but serious events.

Common Side Effects: - Methemoglobinemia: elevated methemoglobin levels causing reduced oxygen delivery. - Nitrogen dioxide formation: irritant gas produced from nitric oxide oxidation. - Rebound pulmonary hypertension: increase in pulmonary pressure after abrupt discontinuation.

Serious or Rare Side Effects: - Severe methemoglobinemia: symptomatic hypoxia requiring medical intervention. - Persistent pulmonary hypertension: prolonged elevation after therapy cessation. - Acute hypotension: sudden drop in systemic blood pressure that may lead to dizziness or shock.

When using Inoxgen, clinicians should observe specific safety measures to minimize risks.

- Monitor methemoglobin levels: perform regular blood tests during therapy. - Avoid abrupt discontinuation: taper dosage to prevent rebound pulmonary hypertension. - Use compatible delivery system: ensure proper ventilation equipment to avoid gas contamination. - Contraindicated in severe anemia: risk of further oxygen‑carrying impairment. - Pregnancy and lactation: limited data; use only if potential benefit outweighs risk. - Store at ambient temperature: keep cylinder in original packaging, protect from heat and direct sunlight.

Inoxgen can interact with other agents that affect the nitric oxide pathway or vascular tone.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause excessive vasodilation and hypotension. - Methylene blue: antagonizes nitric oxide effect and can precipitate methemoglobinemia. - Inhaled anesthetics that scavenge nitric oxide: reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Other vasodilators (e.g., nitroglycerin): additive blood pressure lowering. - Bronchodilators (e.g., albuterol): may enhance hypotensive response. - Blood transfusions: can influence methemoglobin formation and oxygen delivery.